4DMT to Present Interim Clinical Data from INGLAXA Phase 1/2 Trials of 4D-310 for Fabry Disease Cardiomyopathy at 19th Annual WORLDSymposium™
16 févr. 2023 16h05 HE
|
4D Molecular Therapeutics, Inc.
Company to host live webcast on Wednesday, February 22, at 4:30 p.m. ESTPlatform presentation to be presented at WORLDSymposium™ on Saturday, February 25 EMERYVILLE, Calif., Feb. 16, 2023 (GLOBE...
4D Molecular Therapeutics to Participate in the SVB Securities Global Biopharma Conference
08 févr. 2023 16h05 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, ‘4DMT’), a clinical-stage biotherapeutics company harnessing the power of directed evolution for...
4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150 Genetic Medicine for the Treatment of Diabetic Macular Edema
02 févr. 2023 16h05 HE
|
4D Molecular Therapeutics, Inc.
4D-150 Phase 2 SPECTRA clinical trial for diabetic macular edema enrollment is expected to initiate in Q3 2023Initial Phase 1 PRISM clinical trial with 4D-150 for wet age-related macular degeneration...
4D Molecular Therapeutics Announces Updates on Clinical Pipeline and Additional Preclinical Programs
09 janv. 2023 09h00 HE
|
4D Molecular Therapeutics, Inc.
Expands Large Market Ophthalmology Portfolio Following Positive Clinical Data in wet Age-Related Macular Degeneration to Include Diabetic Macular Edema Clinical Program and Geographic Atrophy...
4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2022 Conference
21 nov. 2022 16h05 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted...
4D Molecular Therapeutics Announces Interim Clinical Data from On-going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD)
14 nov. 2022 07h30 HE
|
4D Molecular Therapeutics, Inc.
Cohort 1 patients (n=5) received a single intravitreal injection of 4D-150 (3E10 vg/eye); these patients were high need patients who in the 12 months preceding trial enrollment had a mean annualized...
4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-150 for Wet AMD to be Released Monday, November 14, 2022
10 nov. 2022 16h05 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted...
4D Molecular Therapeutics Reports Third Quarter 2022 Financial Results
09 nov. 2022 16h05 HE
|
4D Molecular Therapeutics, Inc.
- Interim clinical trial data from 4DMT’s Phase 1/2 clinical trial of 4D-710 for the treatment of cystic fibrosis lung disease was presented at North American Cystic Fibrosis Conference on November 3,...
4D Molecular Therapeutics Announces Interim Clinical Data from Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease at NACFC 2022
03 nov. 2022 09h45 HE
|
4D Molecular Therapeutics, Inc.
Cohort 1 lung bronchoscopy sample results demonstrate widespread delivery and expression of the 4D-710 CFTR∆R transgene in 100% of samples from all three patients Cohort 1 safety and tolerability...
4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease to be Presented at NACFC 2022
26 oct. 2022 16h05 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted...